Background In the pivotal LIBERTY 1 and 2 trials and long-term extension study, once-daily
relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone …

Objective In the pivotal LIBERTY 1 and 2 trials and Long-Term Extension (LTE) study, once-
daily relugolix combination therapy (Rel-CT: relugolix 40 mg, estradiol 1 mg, norethindrone …

Background In the LIBERTY Long-Term Extension study, once-daily relugolix combination
therapy (40 mg relugolix, estradiol 1 mg, norethindrone acetate 0.5 mg) substantially …

METHODS: This randomized, double-blind, placebo-controlled, phase 2 study was
designed to evaluate relugolix 10 mg, 20 mg and 40 mg administered orally once daily for …

An oral fixed-dose combination of relugolix/estradiol/norethisterone (also known as
norethindrone) acetate (Ryeqo®; Myfembree®) has been approved for the management of …

Background Uterine fibroids are a common cause of heavy menstrual bleeding and pain.
Treatment with the combination of relugolix (an oral gonadotropin-releasing hormone …

Objective To evaluate the efficacy and safety of 24 weeks of treatment with the oral GnRH
receptor antagonist, relugolix, in combination with estradiol (E2) and norethindrone acetate …

Background Symptomatic uterine fibroids are burdensome to live with; they are associated
with symptom-related distress, affect daily activities, and reduce health-related quality of life …

What is this summary about? This is a summary of research studies (known as clinical trials)
called LIBERTY 1 and LIBERTY 2. The LIBERTY 1 and LIBERTY 2 studies looked at how …

Background Uterine fibroids are hormone-responsive neoplasms that are associated with
heavy menstrual bleeding. Elagolix, an oral gonadotropin-releasing hormone antagonist …